Lineage Cell Therapeutics (LCTX) Total Liabilities (2010 - 2026)

Lineage Cell Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $56.8 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 66.69% year-over-year to $56.8 million; the TTM figure through Mar 2026 stood at $56.8 million (up 66.69% YoY), while the FY2025 annual figure was $69.2 million, up 91.23% from the prior year.
• Total Liabilities for Q1 2026 stood at $56.8 million, down from $69.2 million in the prior quarter.
• The five-year high for Total Liabilities was $69.2 million in Q4 2025, with the low at $31.8 million in Q3 2024.
• The 5-year median for Total Liabilities is $43.7 million (2025), against an average of $46.8 million.
• Peak annual rise in Total Liabilities reached 422.12% in 2022, while the deepest fall reached 38.16% in 2022.
• Lineage Cell Therapeutics' Total Liabilities stood at $51.7 million in 2022, then decreased by 24.61% to $39.0 million in 2023, then fell by 7.15% to $36.2 million in 2024, then surged by 91.23% to $69.2 million in 2025, then decreased by 17.91% to $56.8 million in 2026.
• Business Quant data shows LCTX's Total Liabilities at $56.8 million in Q1 2026, $69.2 million in Q4 2025, and $68.8 million in Q3 2025.